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1. Introduction 
When thrombi are formed, infiltration of leukocytes including neutrophils and macrophages 
follows in and around the thrombi. On the other hand, in inflammatory lesions where 
infiltration of leukocytes is observed, thrombi are often observed. When thrombi are 
formed, activated platelets release a lot of substances while adhering to subendothelial 
connective tissues, recruiting other platelets and aggregating together. In these regions with 
thrombus formation or platelet activation, it is possible that platelets affect leukocytic 
function via the action of the released products, since the substances released from platelets 
include factors that activate [1-14] and suppress [15-22] neutrophilic functions. 
In experiments using human platelets and neutrophils, we found that platelets release 
several neutrophilic phagocytosis activators. Among substances released from activated 
platelets, ATP and ADP have been reported to activate iC3b receptor-mediated phagocytosis 
[1, 2, 23], and some prostaglandins including PGE2, PGF2and thromboxane B2 and 
macromolecular activators of phagocytosis from platelets (MAPPs) activate Fc receptor-
mediated phagocytosis.  
MAPPs have two subsets, l-MAPP (3x105 Da) and s-MAPP (1.5x105 Da) [24, 25]. Platelets 
stored in the form of platelet-rich plasma lose the capacity to release MAPPs but recover it if 
incubated with the plasma-derived precursors of MAPPs (precursors of l-MAPP and s-
MAPP, 3x105 Da and 1.5x105 Da, respectively) and thrombin in the presence of Ca++ [26]. It 
was suggested that the loss of platelet ability to release MAPPs is due to escape of the 
precursors and thrombin during storage with CPD (citrate-phosphate-dextrose) solution. It 
is possible to produce MAPPs using stored platelet-derived lysate by stimulation with 
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thrombin or trypsin in the presence of the precursors [27]. It has also been suggested that the 
precursors of l-MAPP and s-MAPP are polymerized transferrins, probably of tetrameric and 
dimeric forms, respectively [28].  
As for the production of MAPPs in platelets, it was suggested that GP Ib-bound thrombin 
reacts with a high-molecular-weight substance (HMW activator) to release a low-molecular-
weight substance (LMW activator) [29], which can produce MAPPs from the precursors 
directly.  
In an ultracentrifugation study of the platelet lysate, the HMW activator activity was 
observed in the HDL fraction. Anti-apolipoprotein A1 antibody abolished the HMW 
activator function from the HDL fraction of the platelet lysate. These findings suggest that 
the HMW activator belongs to HDL. In an affinity chromatography study of the protein 
obtained from the HDL-rich fraction of the platelet lysate using an anti-apolipoprotein CIII 
(Apo CIII) column, it was suggested that LMW activator is derived from Apo CIII. In fact, it 
was observed that the commercially available Apo CIII could produce LMW activator by the 
activity of thrombin [30]. 
The purpose of this study was to determine the structure of the LMW activator. 
2. Materials and methods 
This study was approved by the local institutional review board of our university hospital. 
The procedures followed were in accordance with the Helsinki Declaration of 1975, as 
revised in 1983. 
2.1. Phagocytosis experiment 
The phagocytosis experiments were performed according to a method previously described 
[30]. Briefly, neutrophils were separated from heparinized venous blood from healthy 
volunteers by centrifugation on MonoPoly resolving medium (ICN Biochemicals Japan, 
Tokyo, Japan). After washing of neutrophils in phosphate-buffered saline (PBS) (Sigma, St. 
Louis, MO), one thousand neutrophils in 5 l of PBS were attached to the surface of a Terasaki 
microplate well (Nunc, Roskilde, Denmark) by centrifugation at 160 g for 2 minutes. Then, 
stimulation was performed with 10 l of the test material in PBS supplemented with 1% 
bovine serum albumin (Sigma) (PBS-BSA) at 37 °C for 15 minutes. After washing, the 
neutrophils were incubated with 5,000 sheep red blood cells (SRBCs) in 5 l of RPMI 1640 
medium supplemented with 1% BSA and a one-hundredth volume of anti-SRBC rabbit IgG at 
37 °C for 25 minutes under 5% CO2. After lysing the unphagocytosed SRBCs using a Tris-
buffered ammonium chloride solution [31] and fixation with 1% glutaraldehyde (Sigma) in 
PBS, the phagocytosed SRBCs were counted under a light microscope.  
All phagocytosis experiments were performed in triplicate. Mean numbers of ingested 
SRBCs per neutrophil in a well were calculated. Then, means of three wells were obtained. 
The results are expressed as phagocytic indices normalized by the phagocytic activity of the 
PBS-BSA control taken as 100.  
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2.2. Production of MAPPs in vitro    
2.2.1. Preparation of the precursors of MAPPs using holo-transferrin 
Precursors of MAPPs were produced artificially using holo-transferrin (Sigma) according to 
a method described previously [28, 30]. Briefly, the peak fraction of holo-transferrin in 
Superdex 200 (GE Healthcare UK Ltd., Buckinghamshire, England) gel filtration was 
incubated on ice for 15 min with 0.2% glutaraldehyde (Sigma) to induce polymerization [32], 
and subjected to filtration again. The fractions obtained at the same elution volumes as the 
conventional l-MAPP (tetramer transferrin-rich fraction) and s-MAPP (dimer transferrin-
rich fraction) were adjusted to an optical density of 0.04 at 280 nm with PBS and used as 
precursors of l-MAPP and s-MAPP, respectively.  
2.2.2. Preparation of LMW activators 
Apo CIII (Chemicon International Inc., Temecula, CA) was adjusted to a concentration of 10 
g/ml in PBS and incubated with 0.1 unit/ml human thrombin (thrombin) (Sigma) or 1 
unit/ml bovine trypsin (trypsin) (Sigma) at 37 °C for 30 minutes, and then applied on a PD10 
column (GE Healthcare UK Ltd.) to obtain the low-molecular-weight fraction, which was 
serially diluted x10 and used as the LMW activator. 
Another Apo CIII （10 g/ml） was incubated with 0.1 unit/ml thrombin or 1 unit/ml 
trypsin and gel-filtered through a Superdex peptide column (GE Healthcare UK Ltd.) 
(elution buffer, PBS; elution speed, 0.5 ml/minute; fraction volume, 1 ml each) to obtain 
LMW activator fraction.  
Samples of the low-molecular-weight fraction of variously prepared platelet-related 
materials including platelet release products and platelet lysate (see below for details) were 
obtained using PD-10 columns.  
Some peptides associated with Apo CIII were synthesized artificially, and the activity as an 
LMW activator was examined. 
2.2.3. Preparation of MAPPs using LMW activators and precursors of MAPPs 
To form MAPPs, 1 ml of appropriately diluted LMW activator derived from Apo CIII, 
platelet release products or artificially produced peptides was incubated with 10 l of 
precursor of l-MAPP or s-MAPP at 37 °C for 30 minutes. 
2.3. Preparation of platelet release products using platelets from platelet-rich 
plasma 
To prepare fresh and stored platelets, heparinized venous blood was mixed with 13 vol% 
citrate-phosphate-dextrose (CPD) solution and centrifuged at 60 g for 20 minutes at 20 °C. 
The platelet-rich plasma, which was contaminated by less than one erythrocyte per 1,000 
platelets, was transferred into another plastic tube and stored at 20 °C in a water bath with 
agitation once a second for 0, 72 or 120 hours.  
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These platelets were washed twice in PBS supplemented with 6.7 mM EDTA and twice in 
PBS, and adjusted to a concentration of 4x105/l. The platelet suspension was stimulated 
with 0.1 unit/ml thrombin at 37 °C for one minute in the presence or absence of 4 mEq/l Ca++, 
then cooled immediately on an ice-water bath and centrifuged at 960 g for 15 minutes at 4 °C 
to obtain the platelet release products in the supernatant.  
2.4. Preparation of platelet lysate 
Platelet suspensions obtained from platelet-rich plasma as described above were frozen at -
15 °C, thawed and centrifuged at 1,500 g for 30 minutes. The supernatant was used as the 
platelet lysate.  
2.5. Peptide synthesis 
Peptides such as S1-K21, H18-R40, H18-K24, H18-K21 and T22-K24 of Apo CIII were 
synthesized by Sawady Technology (Tokyo, Japan). Other peptides that contain part or all of 
H18-K24 (HATKTAK) of Apo CIII were produced by Thermo Fisher Scientific GmbH (Ulm, 
Germany).  
2.6. Inhibition of the LMW activator activity by anti-HATKTAK rabbit IgG 
antibody 
Antibody against HATKTAK was raised in a rabbit by intracutaneous injection of keyhole-
limpet-conjugated CHATKTAK (6 injections at 2-week intervals) by Sigma Aldrich Japan 
(Ishikari city, Japan). The IgG antibody was refined using a protein A column. The control 
IgG antibody was obtained from the same rabbit at day 0 of immunization. 
By indirect enzyme-linked immunosorbent assay (ELISA) [33], specificity of the anti-
HATKTAK rabbit antibody was examined. 100 l of antigens involving Apo CIII and Apo 
CIII-related peptides (1 g/ml in PBS) was immobilized to each well of a polystyrene 
microplate by incubation at 4 °C overnight. 1000-fold-diluted anti-HATKTAK rabbit 
antibody or l000-fold-diluted anti-Apo CIII gout IgG (Gene Tex, Inc., San Antonio, TX) was 
used as the primary antibody. Peroxidase-conjugated anti-rabbit IgG (Fab’) or anti-goat IgG 
(Fab’) (Histofine simple stain MAX-PO(R) or -PO(G), respectively, Nichirei Bioscience, 
Tokyo, Japan) was used as the secondary antibody. Substrate solution consisted of 10 ml of 
0.5 M citrate buffer, 10 ml of 0.3% hydrogen peroxide and 10 mg of orthophenylene diamine 
(Wako, Osaka, Japan). 2 M sulfuric acid was used as a stopping solution. Absorbance was 
determined at 450 nm in a model 550 microplate reader (Bio-Rad, Tokyo, Japan). 
To examine the effect of anti-HATKTAK antibody on an LMW activator, a x102-diluted low-
molecular-weight fraction of the platelet release products prepared from fresh platelet- rich 
plasma and a x106-diluted one from platelet-rich plasma stored for 120 hours were prepared. 
Then, they were incubated with a one-hundredth volume of anti-HATKTAK IgG or control 
IgG at room temperature for 30 min, applied to a protein A column to remove the immune 
complexes and the residual antibodies, and used as the source of the LMW activator. 
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2.7. Ion exchange chromatography 
Cation exchange chromatography was performed using a MONO S HR5/5 column (GE 
Healthcare UK Ltd.). Samples were dissolved in 20 mM Tris-HCl, pH 8.0 (buffer A). The 
adsorbed materials were recovered by elution with a linear increase in buffer B (buffer A + 1 
M NaCl). 
2.8. Assessment of peptide concentrations using the o-phthalaldehyde (OPA) 
fluorescent method 
Peptide concentrations were assessed according to the OPA fluorescent method with intact 
protein [34]. Fluorescence was measured with an excitation wavelength of 340 nm and an 
emission wavelength of 450 nm using a spectrofluorometer (FP-6300, JASCO, Tokyo, Japan). 
2.9. Mass spectrometry 
Matrix-associated laser desorption/ionization time-of-flight mass spectrometry was performed 
with a Voyager System 4314 (Applied Biosystems, Foster City, CA) in the reflector time-of-
flight configuration at an acceleration voltage of 25 kV with delayed ion extraction. Samples 
were diluted 1:1 with a freshly prepared matrix solution consisting of 10 mg/ml -cyano-4-
hydroxycinnamic acid (Sigma) in 20% acetonitrile with 0.1% trifluoroacetic acid. Aliquots of 1 
l were deposited on a metallic sample holder and analyzed immediately after drying in a 
stream of air. Mass scale calibration was performed externally. 
2.10. Immunohistochemistry 
Coagulation of the fresh peripheral blood taken without anticoagulants was induced in a 
glass tube for 3 hours. This coagulum was formalin-fixed, and paraffin sections of 3 m 
thickness were prepared. After deparaffinization and hydration, antigen retrieval was 
performed by heating in 10 mM citrate buffer (pH 6.0) for 40 minutes. After rinsing in PBS 
and incubation with 2% BSA in PBS at room temperature for 60 minutes, incubation with a 
mixture of rabbit anti-HATKTAK IgG (x1,000 diluted) and murine anti-CD 61 monoclonal 
IgG (Dako Japan, Tokyo, Japan) (x100 diluted) at 4 °C overnight was performed followed by 
incubation with a mixture of Alexa Fluor 594-conjugated anti-rabbit IgG (x200 diluted) and 
Alexa Fluor 488-conjugated anti-murine antibody (x200 diluted) (Molecular Probes, Eugene, 
OR, USA). The fluorescent signals were viewed under a confocal microscope (Bio-Rad 
Radiance 2100). As a control experiment, an identical immunohistochemical procedure with 
omission of the primary antibodies was performed. 
2.11. Assay of concentrations of Apo CIII, apolipoprotein AI (Apo AI) and 
apolipoprotein B100 
Concentrations of Apo CIII, Apo AI and Apo B100 in the platelet lysate were assayed by 
ELISA using commercially available assay kits for Apo CIII (AssayPro, St. Charles, MO), 
Apo AI (Mabtech AB, Nacka Strand, Sweden) and Apo B100 (Mabtech AB), respectively. 
 
Lipoproteins – Role in Health and Diseases 726 
 
Figure 1. Characterization of the LMW activator produced from Apo CIII. A. MAPP formation using 
Apo CIII. To prepare LMW activator, 10 g/ml Apo CIII was treated with 0.1 unit/ml thrombin or 1 
unit/ml trypsin, and then diluted serially x10. The activity of each diluted sample as LMW activator was 
examined. B. MONO S cation exchange chromatography of thrombin-treated Apo CIII (10 g). MAPPs 
were generated using each fraction at a dilution of x102 and one of the precursors of MAPPs. C. MONO 
S cation exchange chromatography of trypsin-treated apolipoprotein CIII (10 g/ml). MAPPs were 
generated using each fraction at a dilution of x104 and one of the precursor of MAPPs. D. Superdex 
peptide gel filtration of thrombin-treated Apo CIII (10g/ml). Formation of MAPPs was achieved using 
each fraction at a dilution of x102 and one of the precursors of MAPPs. E. Superdex peptide gel filtration 
of trypsin-treated Apo C-III (10 g/ml). Formation of MAPPs was achieved using each fraction at a 
dilution of x104 and one of the precursors of MAPPs. F. Molecular weight determination of the LMW 
activator with comparisons with those of Apo CIII-derived peptides. G. Amino acid sequence of Apo 
CIII, distributions of basic (+) and acidic (-) amino acids and sugar binding amino acid (T74) in Apo CIII. 
The amino acid sequence is cited from the database of GenPex (NCBI Protein DataBase, 
http://www.ncbi.nlm.nih.gov/protein). A, B, C, D and E were performed using the precursor of s-MAPP.  
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2.12. Statistics 
In this study, the differences were analyzed using Mann-Whitney test, Kruskal-Wallis test, 
paired t test or Wilcoxon test. A P value of less than 0.05 was considered significant. 
3. Results 
3.1. LMW activator is considered to be HATKTAK 
As it was shown in a previous study that both thrombin and trypsin could produce a 
substance with LMW activator activity from platelet lysate [27] and that incubation of Apo 
CIII with thrombin resulted in production of LMW activator, Apo CIII was treated with 
thrombin or trypsin and the LMW activator activities produced were compared to 
determine whether LMW activators produced by these enzymes are the same substance. 
Both thrombin and trypsin could produce LMW activator activity, but 1 unit/ml trypsin 
could produce LMW activator 100 to 1,000 times more effectively than 0.1 unit/ml thrombin 
(Figure 1A). 
The LMW activator activities prepared using thrombin and trypsin appeared at the same 
NaCl concentration of the MONO S cation exchange chromatography (0.2 M NaCl, pH 8.0) 
(Figure 1B and Figure 1C, respectively), and at the same elution volume (16 ml) of the 
Superdex peptide gel filtration (Figure 1D and Figure 1E, respectively), which corresponds 
to the approximate molecular size of 800 Da (Figure 1F). These findings suggest that the two 
LMW activators are the same substance.  
The fact that LMW activator can be produced by trypsin digestion of Apo CIII suggests that 
the C terminal of LMW activator consists of K or R [35]. LMW activator is suggested to be 
one of the basic peptides that would appear after trypsin digestion of Apo CIII (S1-K24, 
H18-R40, H18-K24, H18-K21, T22-K24) (see Figure 1G for the sequence of Apo CIII, 
distribution of basic and anionic amino acids and the sugar binding amino acid). These 
peptides were artificially produced and filtered on the Superdex peptide column to use as 
molecular size markers. The optical peaks of OPA fluorescence and LMW activator activity 
by H18-K24 (HATKTAK) appeared at the same elution volume of Superdex peptide gel 
filtration corresponding to Apo CIII-derived LMW activator (Figure 1D, 1E, 2A and 2B). In 
MONO S cation exchange chromatography, the action of HATKTAK as LMW activator was 
recovered at the fraction with the same NaCl concentration (0.2 M NaCl, pH 8.0) (Figure 2C) 
as the Apo CIII-derived LMW activator (Figure 1B and 1C). 
3.2. Only HATKTAK among examined peptides showed MAPP-forming activity 
Among the peptides used for calibration on Superdex peptide gel filtration (Figure 1F), H18-R40 
and H18-K21 were separated in the fractions near to HATKTAK (LMW activator). The activity 
of these peptides as LMW activators were examined. Only HATKTAK showed LMW activator 
activity with a peak at 1 nM (Figure 2D). Then, some Apo CIII-derived peptides that contain 
part or all of H18-K24 were examined for their LMW activator activity. All of them were used at 
a concentration of 1 nM. Only HATKTAK showed MAPP-forming activity (Table 1).   
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Figure 2. HATKTAK functions as the LMW activator. A. Superdex peptide gel filtration of HATKTAK 
(200 g, 0.2 ml). The peptide concentration of each fraction was measured by the OPA fluorescent 
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method. The inset shows the standard graph for the assay of HATKTAK. B. MAPP formation using 
fractions of Superdex peptide gel filtration of HATKTAK (200 g, 0.2 ml) at a dilution of x106 by 
incubation with one of the precursors of MAPPs. C. MONO S cation exchange chromatography of 1 
g/ml HATKTAK. MAPPs were generated by incubation of each fraction from the chromatography at a 
dilution of x104 and one of the precursors of MAPPs. D. MAPP formation using peptides containing 
part of the sequence of apolipoprotein CIII. Each peptide was serially diluted x10 and incubated with 
one of the precursors of MAPPs. B, C and D were performed using the precursor of s-MAPP. 
  Peptides Precursor of l-MAPP Precursor of s-MAPP 
  HATK - - 
  HATKT - - 
  HATKTA - - 
  HATKTAK + + 
  HATKTAKD - - 
                    K - - 
                 AK - - 
              TAK - - 
      ATKTAK - - 
KHATKTAK - - 
Table 1. MAPP formation from precursors of MAPPs with peptides derived from K16 to D25 of Apo 
CIII (KHATKTAKD) 
3.3. LMW activator activity in platelet release products and platelet lysate 
In the next part of the study, the LMW activator activities in variously prepared samples 
including platelet release products and platelet lysate were compared to determine whether 
platelets release LMW activator. Platelet release products were prepared using platelets 
from fresh and stored platelet-rich plasma. The reason why we examined platelet release 
products prepared from stored platelet-rich plasma along with those prepared from the 
fresh equivalent is that platelet releasate from stored platelet-rich plasma was expected to 
contain a higher concentration of LMW activator because platelets lose the precursors of 
MAPPs during storage [26]. From all of these samples, the low-molecular-weight fraction 
was separated using PD10 columns, and the activity corresponding to LMW activator was 
compared by the largest dilution from the original sample for which a phagocytic index 
higher than 150 was recorded (effective dilution).  
1 ng/ml HATKTAK and platelet release products from fresh platelets stimulated with 4 
mEq/l Ca++ and 0.1 unit/ml thrombin showed an effective dilution of 102 to 103, whereas 
fresh platelets stimulated only with 4 mEq/l Ca++ or 0.1 unit/ml thrombin for 1 minute 
showed far lower effective dilution, and platelet release products prepared from platelets 
after storage for 72 hours and 120 hours in the form of platelet-rich plasma showed 
extremely high effective dilution (103 to 105, platelets from platelet-rich plasma stored for 72 
hours; 107 to 108, those stored for 120 hours). None of the platelet lysate produced from 
platelets in fresh and stored platelet-rich plasma showed LMW activator activity (Figure 3). 
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To confirm whether these LMW activator activities were by the same substance, Superdex 
peptide gel filtrations of the low-molecular-weight fractions of platelet release products 
prepared from fresh platelets (A), and those stored for 72 hours (B) and 120 hours (C), with 
stimulation with 0.1 unit/ml thrombin in the presence of 4 mEq/l Ca++ were performed. 
Fractions of the gel filtrations were diluted x102 (A), x104 (B) and x106 (C). All of these 
samples showed LMW activator activity at the fraction corresponding to HATKTAK 
(compare Figure 4A, 4B and 4C with Figure 2B). 
3.4. Inhibition of LMW activator activity by anti-HATKTAK antibody 
Then, to obtain evidence of the existence of HATKTAK in the platelet release products, 
actions of an anti-HATKTAK rabbit antibody against LMW activator activity were 
examined.  
 
Figure 3. Comparisons of effective dilution of LMW activator in platelet release products and platelet 
lysate prepared using platelets that were obtained from platelet-rich plasma stored for 0 hours, 72 hours 
and 120 hours. A black circle means a case with the effective dilution of LMW activator indicated by the 
horizontal axis. *, P<0.01 with the Mann-Whitney test, and #, P<0.01 with the Kruskal-Wallis test. All 
experiments were performed using the precursor of s-MAPP. 
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Figure 4. Comparisons of molecular size of LMW activator in platelet release products prepared using 
(A) platelet release products using fresh platelets stimulated with 0.1 unit/ml thrombin in the presence 
of Ca++; (B) platelet release products using platelets stored for 72 hours stimulated with 0.1 unit/ml 
thrombin in the presence of Ca++; (C) platelet release products using platelets stored for 120 hours 
stimulated with 0.1 unit/ml thrombin in the presence of Ca++. The LMW activator activity of each 
fraction was examined at dilutions of x102 (A), x103 (B) and x106 (C). All experiments were performed 
using the precursor of s-MAPP. 
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ELISA revealed that anti-HATKTAK reacted strongly to H18-K24 (HATKTAK), K17-K24 and 
S1-K24 of Apo CIII, but very weakly to Apo CIII and H18-D25 of Apo CIII, whereas anti-Apo 
CIII goat antibody showed a positive reaction only to Apo CIII (Figure 5A and 5B, respectively).  
 
Figure 5. Effects of anti-HATKTAK antibody on LMW activator activity. A, ELISA using anti-
HATKTAK rabbit IgG and control rabbit IgG against Apo CIII and H18-K24 of Apo CIII. B, ELISA 
using anti-HATKTAK rabbit IgG and anti-Apo CIII gout IgG against peptide associated with Apo CIII, 
HATKTAAK and Apo CIII. C, Effects of control rabbit IgG and anti-HATKTAK rabbit IgG on LMW 
activator activity in the low-molecular-weight fraction of platelet release products prepared from 
platelets of fresh platelet-rich plasma. D, Effects of control rabbit IgG and anti-HATKTAK rabbit IgG on 
LMW activator activity in the low-molecular-weight fraction of platelet release products prepared using 
platelets of platelet-rich plasma stored for 120 hours. In C and D, figures reveal the result of 
experiments using the precursor of s-MAPP. The bars in the figure show the average.  
*, P<0.01; **P<0.05 by paired t test. 
Both LMW activators derived from fresh platelet and platelets stored for 120 hours were 
inhibited by the anti-HATKTAK IgG antibody (Figure 5C and 5D, respectively). 
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3.5. Evidence of existence of HATKTAK by mass spectrometry 
In mass spectrometry, HATKTAK showed m/z 756 (Figure 6A). Although it was impossible 
to show the existence of a substance with m/z 756 in thrombin-digested Apo CIII (10 g/ml) 
and in platelet release products released from fresh platelets and those stored for 72 hours 
(data not shown), a substance with m/z 756 was detected in the trypsin-treated Apo CIII (10 
g/ml) (Figure 6B) and platelet release products prepared from platelets stored for 120 hours 
(Figure 6C). 
 
 
Figure 6. Mass spectrometry of HATKTAK, trypsin-digested Apo CIII and platelet release products 
from platelets of platelet-rich plasma stored for 120 hours. A, 1 mg/ml HATKTAK in PBS;  B, 10 g/ml 
Apo CIII digested with 1 unit/ml trypsin; and C, platelet release products using platelets of platelet-rich 
plasma stored for 120 hours. Platelets were stimulated with 0.1 unit/ml thrombin in the presence of Ca++. 
 
 
Figure 7. Confocal microscopic images of double staining for the anti-HATKTAK antibody (visualized 
as red in A), and the anti-CD61 antibody (visualized as green in B). The colocalization of two antibodies 
is indicated by the conversion of green and red to yellow (C). Scale bar indicate 20 m. 
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3.6. Immunohistochemical evidence of existence of HATKTAK in activated 
platelets 
To show the existence of HATKTAK in activated platelets, an immunohistochemical study 
of the blood coagula was performed. Platelets in the coagula showed positive reactions with 
both anti-HATKTAK and anti-CD 61 antibodies simultaneously (Figure 7). 
3.7. Increases in concentrations of Apo CIII, Apo AI and Apo B100 in the platelet 
lysate 
As the LMW activator activity in the products released from platelets increased markedly if 
stored platelets were used, concentrations of Apo CIII, Apo AI and Apo B100 in the platelet 
lysate prepared from platelet-rich plasma stored for 120 hours at 20 °C were compared with 
those prepared from fresh equivalent plasma to determine whether lipoproteins are 
internalized by platelets during storage of platelet-rich plasma. All of Apo CIII, Apo AI and 
Apo B100 in the lysate from 120 hour-stored platelets were high (20 ng/ml, 18 ng/ml and 252 
ng/ml in average, respectively), whereas those from platelet-rich plasma before storage were 
very low (1.4 ng/ml, 0.6 ng/ml and 130 ng/ml on average, respectively) (Figure 8).  
 
Figure 8. Concentrations of Apo CIII, Apo AI and Apo B100 in the platelet lysate. Concentrations of 
Apo CIII, Apo AI and Apo B100 in the platelet lysate, which were prepared from platelet-rich plasma 
before (0 hours) and after storage for 120 hours (120 hours), were determined using commercially 
available ELISA kits. The bars in the figure show the average. **, P<0.05 by Wilcoxon test. 
4. Discussion 
Since we found MAPPs in platelet release products, we have investigated their structure 
and the mechanisms of production and release by platelets. When fresh platelets are 
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stimulated by thrombin, collagen or centrifugation in the presence of Ca++, MAPPs are 
released. When platelets are stored longer than 72 hours in the form of platelet-rich plasma, 
they lose the capacity to release MAPPs. It is speculated that this is because platelets lose 
their contents of thrombin and precursors of MAPPs during storage in the form of platelet-
rich plasma. They recover the MAPP-releasing function by washing with PBS and 
incubation with plasma-derived precursors of MAPPs and thrombin in the presence of 
Ca++ [26]. This suggests that some platelet factor other than thrombin and the precursors of 
MAPPs is necessary for MAPP production. To analyze this factor, the action of the platelet 
lysate obtained by freeze-thaw of stored platelets on MAPP formation was investigated. 
By incubation of the platelet lysate with thrombin and the plasma-derived precursors, it 
was possible to produce MAPPs. When producing MAPPs using plasma-derived 
precursors and the platelet lysate, we found that trypsin instead of thrombin can produce 
MAPPs [27].  
After we found that the plasma precursors of MAPPs are dimer and tetramer transferrins 
[28], we produced precursors of MAPPs by glutaraldehyde treatment of commercially 
available holo-transferrin and used them to produce MAPPs in vitro. 
In the former study [30], we found that Apo CIII associated with the high-density 
lipoprotein in platelet lysate can be the source of LMW activator. In this study, we compared 
the LMW activators produced from Apo CIII by the actions of thrombin and trypsin. It was 
revealed that both LMW activators appeared in the fractions of the same elution volume of 
Superdex peptide gel filtration and in the fractions with the same NaCl concentration of 
MONO S cation exchange chromatography. These findings suggest that the LMW 
activators produced by thrombin and trypsin are the same substance. The fact that trypsin 
can form LMW activator suggests that LMW activator is a peptide with a C-terminal 
amino acid of lysine or arginine and that the N-terminal is an amino acid next to lysine or 
arginine in the amino acid sequence of Apo CIII. It can be asserted that the action of 
thrombin in LMW activator formation occurs by its trypsin-like activity, although the 
activity of thrombin to release LMW activator from Apo CIII is far lower than that of 
trypsin. Cation exchange chromatography in this study revealed that the LMW activator 
is cationic, suggesting that it is a peptide rich in basic amino acids. In Apo CIII, K17 to 
K24 is a region rich in basic amino acids, containing four basic amino acids among eight 
amino acids in total. Several candidate peptides for LMW activator that contain all or part 
of the K17 to K24 peptide were raised. By comparing the elution volumes of peaks of 
these peptides with that of LMW activator function on Superdex peptide gel filtrations 
and by examining MAPP formation using these peptides, it was strongly suggested that 
HATKTAK is the LMW activator.  
As for the reaction of thrombin, the most abundant natural substrate of thrombin is 
fibrinogen [36], whereas O’Mullan et al. [37] reported that the action of thrombin to various 
proteins including Apo CIII is more variable and various peptides cleaved from Apo CIII 
appear by the action of thrombin on Apo CIII. Our study revealed that the trypsin-like 
thrombin activity that digests Apo CIII to release HATKTAK is weak, but does in fact exist. 
We have shown that GP-1b-bound thrombin functions in MAPP production [29]. GP-Ib is 
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a high-affinity thrombin receptor on platelets [38-39]. Binding of thrombin with GP-1b 
might enhance the trypsin-like activity of thrombin in platelets.  
To confirm that LMW activator, HATKTAK, is produced by the platelets, we examined the 
LMW activator activity in the low-molecular-weight fractions of variously prepared platelet 
release products. We found that, in the platelet release products prepared using 4x105/l 
fresh platelets (0.1 unit/ml thrombin in the presence of 4 mEq/l Ca++), the LMW activator 
involved is as much as 1 ng/ml HATKTAK.  
By storage of the platelet-rich plasma, release of LMW activator from platelets induced by 
thrombin in the presence of Ca++ increased prominently. It was suggested that the 
concentration of LMW activator released from platelets stored for 120 hours is 10,000 times 
as much as that from fresh platelets.  
One reason for the tremendous increase in LMW activator, HATKTAK, in the released 
products during storage is probably the loss of the precursor of MAPPs during storage, as 
shown in a previous report [26]. It is speculated that, in activated fresh platelets, LMW 
activator (HATKTAK) is produced as much as in stored platelets, but it decreases markedly 
because precursors of MAPPs remove it in fresh platelets. Another possible reason is that 
lipoproteins, apolipoproteins or fragments of apolipoproteins might be transported at high 
levels into platelets from the plasma during storage. In fact, it was shown that the 
concentrations of Apo CIII and Apo A1 in the platelet lysate increased markedly after 
storage of platelets in the form of platelet-rich plasma, but this was still too small to explain 
the observed increase in the effective dilution by as much as 1,000 times.  
Indirect ELISA of the platelet release products using anti-HATKTAK antibody was 
undertaken to prove the existence of HATKTAK. The results were satisfactory if synthesized 
pure peptides were used, and it was shown that the anti-HATKTAK rabbit antibody reacted 
positively to Apo CIII-derived peptides with C-terminal HATKTAK. However, we have not 
succeeded in establishment of a method to analyze HATKTAK in platelet release products. 
It is postulated that some substances derived from the platelet release products interfere 
with the adherence of HATKTAK on the wall of microtiter plate. Therefore, we examined 
the effect of the antibody on the LMW activator function. It was confirmed that the anti-
HATKTAK antibody cancels the activity of the LMW activator in the platelet release 
products from fresh platelet-rich plasma and that stored for 120 hours. Mass spectrometry 
study revealed the presence of a substance corresponding to HATKTAK (m/z 756) in the 
platelet release products from platelets stored for 120 hours. Immunohistochemistry of the 
blood coagula revealed the existence of platelets with double-positive reaction to anti-
HATKTAK and anti-CD61 antibodies. These findings strongly suggest that the LMW 
activator is HATKTAK and is produced and released by platelets.  
A schematic illustration of the probable mechanism of production and release of MAPPs 
and HATKTAK by platelets is depicted in Figure 9. 
At present, the mechanism of how MAPP contributes to neutrophilic phagocytosis 
enhancement after binding to neutrophils is not known. Because MAPPs possess transferrin 
molecules and anti-transferrin receptor antibody inhibits the action of MAPPs [28], it is 
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suggested that the action of MAPPs occurs via the transferrin receptor. As shown 
previously, treatment of neutrophils with MAPP does not result in an increase in the 
number of Fc receptors on neutrophils [40]. This suggests that the effect of MAPP is to 
strengthen the affinity of Fc receptors with the Fc portion of IgG and to internalize more 
foreign materials inside the cell. The necessity of HATKTAK for MAPP function suggests 
that the transferrin receptor might have a site for binding to both transferrin and 
HATKTAK, and the fact that MAPPs consist of multimers (dimer and tetramer) of 
transferrin suggests that transferrin receptors must be fixed at an appropriate distance when 
MAPPs induce enhancement of phagocytosis via the Fc receptors. The mechanisms of how 
the transferrin receptor, which is stimulated by HATKTAK and transferrin, transfers the 
information to Fc receptors remain to be elucidated.  
 
Figure 9. A schematic illustration of the mechanism of production of MAPPs and HATKTAK in 
platelets and their subsequent release.  
In conclusion, we could show that HATKTAK is the LMW activator, which is produced in 
activated platelets and activates MAPPs, and that the residual HATKTAK is released with 
other platelet-related substances including MAPPs.  
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